Oncocytology

 
  Table of Contents    
Review Article
 
Biotherapeutics for human eosinophil associated disorders
Anubha Singh1, Deepak Kumar Singh2, Usha Bhoria3
1Senior Resident, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of Labor, Noida, Uttar Pradesh, India.
2Junior Specialist, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of Labor, Noida, Uttar Pradesh, India.
3Senior Specialist, Department of Laboratory Services, Employees' State Insurance Corporation Model Hospital, Ministry of labor, Noida, Uttar Pradesh, India.

Article ID: 100007OCYAS2015
doi:10.5348/OCY-2015-7-RA-1

Address correspondence to:
Anubha Singh
Senior Resident, Department of Laboratory Services
Employees' State Insurance Corporation Model Hospital
Noida, Uttar Pradesh
India

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article
Singh A, Singh DK, Bhoria U. Biotherapeutics for human eosinophil associated disorders. Oncocytology 2015;5:1–13.


Abstract
Eosinophils which play an important role in pathophysiology of eosinophil associated diseases (EADs) contain plethora of mediators of inflammation and immune responses, including lipid mediators and eosinophil granules containing secretory cationic proteins. When secreted, they cause significant tissue damage. To circumvent the effects, numerous strategies have been employed for development of biologic medicines for EADs. Strategies used for development of biotherapeutics for EADs include eosinophil modulating therapies, destruction of eosinophils by means of ADCC or opsonization with removal by reticuloendothelial system, targeting key eosinophil survival cytokines and blocking eosinophil migration into inflamed tissues is another promising strategy for the reduction of end-organ manifestation of eosinophilia. EADs are categorized as "orphan" diseases and most of the current treatment options for patients with these conditions are used off-label. Better therapeutic targets that offer enhanced treatment selectivity and benefit for these conditions need to be identified and developed. In this review we provided an overview of potential molecular targets of pharmacotherapy and discussed the potential eosinophil targeting agents, which includes those in preclinical and clinical development for treatment of EADs.

Keywords: Biotherapeutics, Eosinophil, Monoclonal antibody, Eosinophil associated diseases


[HTML Full Text]   [PDF Full Text]

Author Contributions
Anubha Singh – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Deepak Kumar Singh – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Usha Bhoria – Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Authors declare no conflict of interest.
Copyright
© 2015 Anubha Singh et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.



  Home line About Oncocytology line Aim and Scope line Sections line Open Access line Archives
Apply as Editor line Apply as Reviewer line Submit Reviews - Editors line Submit Reviews - Reviewers
Instructions for Authors line Templates to Use line Copyright Form line Author Checklist
Online Submission line Email Submission line Submit Revision line Submit All Forms line Submit Page Proofs
Terms of Service line Privacy policy line Disclaimer line FAQ line Contact: Journal line Contact: Edorium Journals line Site Map
 
  Copyright © 2017. Edorium. All rights reserved.